Board of Directors
Peter has a wealth of experience and has held key senior positions, including Chairman, CEO and CFO in a number of companies in the healthcare industry, and played a significant role in their growth.
Peter spent 12 years at Celltech Group plc (1992–2004) as CFO and Deputy CEO, six years at ProStaken Group plc as Chairman (2007–2013) and interim CEO (2010–2011) and three years as Chairman of Proximagen Neurosciences plc (2009-2012).
Peter is currently Chairman of Abcam plc, Advanced Medical Solutions Plc, Future Plc and Diurnal Plc and Non-Executive Director of Oxford Nanopore Technologies Ltd and Macrotarg Ltd.
Shaun is the Chief Executive Officer of the Clinigen Group and has the responsibility for the Group achieving its key performance indicators and plays a central role in setting the Group strategy.
Shaun has played a pivotal role in the development of Clinigen, joining the company in January 2012 as Chief Operating Officer, when it was a privately owned company with a turnover of £82m.
He was a key part of the executive team that took Clinigen through IPO in September 2012 and, as deputy CEO in 2015 and then CEO from November 2016, has been a fundamental part of the leadership of the impressive strategic growth of the company from £135m market capitalisation in 2012 to its current position as one of the largest companies on the Alternative Investment Market (AIM) on the London Stock Exchange.
In 2017, Shaun oversaw the largest M&A healthcare deal of the year in the UK with the successful acquisition of Quantum Pharma, in addition to acquiring the largest supplier of unlicensed medicines in Japan, IMMC.
Shaun was awarded the Entrepreneur of the Year Healthcare (Western Europe) in 2017 by the European CEO Awards.
Prior to joining Clinigen, Shaun held senior global strategic, commercial and operational roles at Pfizer, Sanofi, Wolters Kluwer Health and the KnowledgePoint360 Group (now part of UDG Healthcare).
Martin joined Clinigen in August 2015 and has over 19 years’ experience working for international, listed companies.
Before Clinigen, Martin worked for Hays plc, Europe’s largest professional recruitment business. He began there as Head of Investor Relations and M&A before becoming Finance Director for the Continental Europe and Rest of World division, which operated across 21 countries with revenues of over £1bn. Prior to that, Martin held several financial roles at the FTSE 100 logistics group, Exel plc (now part of Deutsche Post), including Financial Controller of two of the UK divisions. He is a qualified Chartered Accountant, having trained at PwC in the M&A Transaction Services team.
John has over 30 years’ experience as a corporate lawyer, dealing with corporate finance and commercial contract issues across a number of industries. He was formerly Managing Partner at Ricksons LLP and subsequently became a Partner at DWF LLP.
John is currently the Chairman of the Board of Enigma Group Holdings Ltd.
Ian has considerable experience as both an Executive Director and as a Non-Executive Director. Ian is CEO of F2G Limited.
Ian currently holds positions as Non-Executive Director of Consort Medical plc and Bioventix plc, where he is the Non-Executive Chairman. Ian is also Chairman of the Investment Committee at Cancer Research UK Pioneer Fund, Director of Casewell Consulting Ltd, F2G Ltd, and Wells Stores Ltd, and an Operating Partner at Advent Life Sciences LLP.
Anne has a strong track record within the biopharma sector, bringing with her over 25 years of financial experience with both public and private companies.
Anne is a Chartered Accountant (FCA), and Corporate Tax Adviser (CTA – AITI) and holds a degree in Business studies from Trinity College, Dublin. Previously, she was CFO of BBI Diagnostics Group Ltd and FTSE-listed Vectura Group plc. Prior to her role at Vectura, Anne held a number of senior finance positions at Celltech Group plc, Medeva plc and KPMG.
Anne is CFO of Kymab Ltd a private biopharmaceutical company. She is also a Non-Executive Director of Elementis plc, a FTSE-250 global specialty chemicals company.